Eli Lilly and Company (LLY)
Compared to Estimates, Lilly (LLY) Q1 Earnings: A Look at Key Metrics
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly (LLY) Beats Q1 Earnings and Revenue Estimates
Eli Lilly (LLY) came out with quarterly earnings of $8.55 per share, beating the Zacks Consensus Estimate of $7.06 per share. This compares to earnings of $3.34 per share a year ago.
Eli Lilly cemented its lead in the booming weight-loss drug market with huge sales gains for the first quarter, as focus shifts to new pills
Consumer demand for blockbusters Mounjaro and Zepbound helped offset declining prices for the drugs.
Eli Lilly stock jumps 6% after strong earnings and raised guidance
Eli Lilly reported stronger-than-expected first-quarter earnings and revenue on Thursday, driven by robust demand for its blockbuster weight-loss and diabetes drugs, prompting the company to raise its full-year guidance. The pharmaceutical giant now expects 2026 revenue to range between $82 billion and $85 billion, up from its earlier forecast of $80 billion to $83 billion.
Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket
Revenue tied to Lilly's Zepbound and Mounjaro more than doubles from the same period last year.
Eli Lilly Stock Could Rise Sharply After Earnings
Eli Lilly and Company has declined over 20% since January despite strong anticipated Q1 results and has not participated in the recent market rally. Options market positioning is extremely bearish with high implied volatility, but this may set up a bullish reversal post-earnings due to premium decay. Implied volatility is expected to drop sharply after earnings, potentially forcing market makers and put holders to unwind bearish positions, adding upward pressure to LLY shares.
Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings
Eli Lilly is scheduled to report its latest quarterly earnings ahead of the opening bell Thursday, with shares seen potentially falling to their lowest level in months following the report.
Pharmaceutical Stock Pulling Back Before Earnings
Eli Lilly And Co (NYSE:LLY) stock is down 0.3% to trade at $865.41 at last glance, pulling back alongside the broader market.
LLY Expands Oncology Pipeline With $2.3B Ajax Therapeutics Acquisition
Lilly is set to acquire Ajax Therapeutics for up to $2.3B, gaining a novel JAK2 inhibitor as it ramps up oncology bets and targets unmet needs in MPN treatment.
Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion
AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines.
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
Boehringer Ingelheim said on Tuesday its experimental obesity drug led to average weight loss of up to 16.6% in a late-stage trial, as the unlisted German drugmaker seeks to catch up with obesity drug pioneers Eli Lilly and Novo Nordisk.
Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
